3. Patient characteristics in different subgroup
In the entire cohort, 19 patients (26.8%) received systematic therapy
and 52 patients (73.2%) received secondary cytoreductive surgery (SCS).
Patients who treated with SCS were younger than those with non-SCS.
63.5% and 31.6% patients were initially diagnosed before 50 years in
the SCS and non-SCS subgroup, respectively (P=0.017, Table1). More
patients received myomectomy in SCS subgroup (32.7% vs 0.0%, P=0.003,
Table1). The majority of patients
were assigned to stage I at the time of original diagnosis in SCS
subgroup than in non-SCS subgroup (86.5% vs 52.6%, P=0.008, Table1).
More patients experienced first recurrence after 12 months since
diagnosis in SCS subgroup than in non-SCS subgroup (73.1% vs 47.4%,
P=0.043, Table1).
The recurrent pattern was different in SCS and non-SCS subgroup.
Patients treated with SCS were more likely to experience recurrence in
isolated sites (36.5% vs 5.3%, P=0.009, Table1), and less likely to
recurred in multiple locations (17.3% vs 47.4%, P=0.015, Table1).
Patients treated with SCS were more likely to experience recurrence in
abdominal/pelvic peritoneum (71.2%), abdominal wall (21.2%) and
vaginal cuff (9.6%) (Table 2). Of patients received systematic
treatment, 68.4% and 21.1% had lung metastases and bone metastases,
respectively (Table 2).
4. Secondary
cytoreductive surgery treatment
Of the 52 patients undergoing secondary cytoreductive surgery,
a complete resection with no
residual disease was reported in 47 patients (90.4%) (Table 4). 69.2%
patients had a tumor larger than 5 cm found at secondary
cytoreduction. 38.5% (20/52)
patients received non-genital organ surgeries. 10 (19.2%) patients had
received thoracic surgery because of
lung-only recurrences. Bowel,
bladder surgery was performed in 15.4%, 5.8% of the cases,
respectively. 1 (1.9%) patient had received liver surgery because of
liver recurrence. 34.6% patients had
estimated blood loss more than 500 ml (Table 4).